Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials

Netherlands Journal of Medicine

Volumn 61, Issue 4, 2003, Pages 105-110

  Naber, A H J ^a   de Jong, D J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DIPHENOXYLATE; LOPERAMIDE; SERUM ALBUMIN;

ABDOMINAL MASS; ABDOMINAL PAIN; BODY WEIGHT; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FEVER; GENDER; HEMATOCRIT; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; INTESTINE ENDOSCOPY; INTESTINE FISTULA; INTESTINE RESECTION; MEDICAL ASSESSMENT; MEDICAL PARAMETERS; NAUSEA; PATIENT MONITORING; PATIENT SELECTION; QUALITY OF LIFE; REPRODUCIBILITY; REVIEW; SCORING SYSTEM; SIGMOIDOSCOPY; SYMPTOMATOLOGY; TEMPERATURE MEASUREMENT; TREATMENT OUTCOME; TREATMENT PLANNING; ULCERATIVE COLITIS; WEIGHT REDUCTION; WELLBEING; HOSPITALIZATION;

CLINICAL TRIALS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX;

EID: 0038785702     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: preliminary report on a therapeutic trial. BMJ 1954;2:375-8.
2. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955;2:1041-8.
3. Best WR. Becktel JM. Singleton JW, Kern F jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
4. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979;77:843-6.
5. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-30.
6. Dombal FT de, Softley A. IOIBD report no q: Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut 1987;28:474-81.
7. Harvey FR, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980;1:514.
8. Present DH, Korelitx BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6 mercaptopurine. A long-term, randomized double-blind study. N Engl J Med 1980;302:981-7.
9. Wright JP, Marks IN, Parfitt A. A simple clinical index of Crohn's disease activity - the Cape Town index. S Afr Med J 1985;68:502-3.
10. Myren J, Bouchier IA, Watkinson G, Softley A, Clamp SE, Dombal FT de. The O.M.G.E.. Multinational Inflammatory Bowel Disease Survey 1976-19*82. A further report on 2657 cases. Scand J Gastroenterol Suppl 1984;95:1-27.
11. Mitchell A, Guyatt G, Singer J, et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 1988;10:306-10.
12. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
13. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992;14:15-9.
14. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96.
15. Drossman DA. Measuring quality of life in inflammatory bowel disease. Pharmacoeconomics 1994;6:578-80.
16. Hees PA van, Elteren PH van, Lier HJ van, Tongeren JH van. An index of inflammatory activity in patients with Crohn's disease. Gut 1980;21:279-86.
17. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27-32.
18. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
19. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983-9.
20. Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665-72.
21. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63.
22. Korelitz BI, Sommers SC. Respose to drug therapy in Crohn's disease: evaluation by rectal biopsy and mucosal cell counts. J Clin Gastroenterol 1984;6:123-7.
23. Haens GF, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-7.
24. Talstad I, Gjone E. The disease activity of ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1976;II:403-8.
25. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisone given as single or multiple daily doses for active ulcerative colitis. Scand J Gastroenterol 1978;13:833-7.
26. Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964;5:437-42.
27. Heide H van der, Brandt-Gadel V van den, Tytgat GNJ, et al. Comparison of beclomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis. J Clin Gastroenterol 1988;10:54-8.
28. Sutherland LR, Martin F, Greers S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis and proctitis. Gastroenterology 1987;92:1894-8.
29. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6.
30. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderate active ulcerative colitis. A randomised study. N Engl J Med 1987;317:1625-9.
31. Riley SA, Mani V, Godman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174-8.
32. Eaden JA, Mayberry JF. Colorectal cancer complicating ulcerative colitis: a review. Am J Gastroenterol 2000;95:2710-9.
33. Dick AP, Holt P, Dalton ER. Persistence of mucosal abnormality in ulcerative colitis. Gut 1966;7:355-60.
34. Baron JH, Conell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearance in proctocolitis. BMJ 1964;1:89-92.